Viagra Now Available Intravenously

Recommended Sources

About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Well, not quite. The FDA appoved Pfizer (PFE)’s pulmonary arterial hypertension drug Revatio as an injection in cases where the patient is unable to swallow the tablets. Of course, Revatio (sildenafil) is the same drug as Viagra. It just has a different name and a different set of indications and approvals. The drug works for both ED and AHD.

Pfizer made this obvious reminder:

Do not take Revatio with Viagra …

BNET noted in October that Revatio is turning out to be a nice little earner for Pfizer. Its sales were up 18 percent to $111 million worldwide in Q3 2009. Not huge for a company of Pfizer’s size, but it helped offset an 8 percent decline in Viagra sales to $466 million in the same period.

Tags: Pfizer, Viagra, Jim Edwards, Revatio, intravenous

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Voice your 2cents

Web Buzz:

US FDA approves Pfizer's intravenous Revatio

Scrip News - 78 days 12 hours 34 minutes ago

The US FDA has approved an intravenous formulation of Pfizer's Revatio (sildenafil; also known as Viagra) for the treatment of pulmonary arterial hypertension (PAH). With this approval, Revatio becomes the only FDA-approved phosphodiesterase-5
ED drug gets nod as pulmonary ailment

FiercePharma - 259 days 15 hours 45 minutes ago

File in the "new uses for approved drugs" drawer, in the erectile dysfunction med folder: United Therapeutics has persuaded the FDA to approve Eli Lilly's ED med Cialis as a treatment for pulmonary arterial hypertension. Marketed under the name Adcirca, the drug will compete with treatments from Pfizer (Revatio), Actelion (Tracleer), and Gilead...
Actelion's Tracleer approved for early-stage PAH in US

Scrip News - 183 days 16 hours 19 minutes ago

Actelion has received authorisation from the US FDA to extend the label of its oral pulmonary arterial hypertension (PAH) drug, Tracleer (bosentan), to include patients with mild forms of the disease, classified as WHO functional class
United Therapeutics Gets FDA Approval For Adcirca

Pharmaceutical Business Review - 257 days 56 minutes ago

United Therapeutics has announced that FDA has approved its drug Adcirca(tadalafil). Adcirca is an oral administration drug for the treatment of pulmonary arterial hypertension (PAH
United Therapeutics' inhaled PAH treatment approved in US

Scrip News - 189 days 15 hours 53 minutes ago

The US FDA has approved United Therapeutics' inhaled formulation of treprostinil, Tyvaso, for the treatment of pulmonary arterial hypertension (PAH). Tyvaso is indicated to increase walk distance in patients with NYHA Class III symptoms